Revolution Medicines' Experimental Drug Daraxonrasib Faces High Demand Amid Pancreatic Cancer Treatment
Revolution Medicines has developed an experimental drug called daraxonrasib, which has shown promising results in nearly doubling the overall survival time for pancreatic cancer patients in clinical trials. The drug is currently available through an expanded access program, allowing critically ill patients to receive it outside of clinical studies. However, the high demand for daraxonrasib has led to concerns about its availability. Patients like Amy Johnston, who is battling pancreatic cancer, are anxious about whether they will be able to access the drug in time. Johnston, a 35-year-old mother from Gilbertsville, Pennsylvania, is currently participating in a clinical trial and hopes to access daraxonrasib if her current treatment does not succeed. The small size of Revolution Medicines raises concerns about their ability to meet the demand for the drug. 
